← All indications
Peripheral Vascular Diseases
Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.
Subtype terms (7)
More specific conditions that are subtypes of Peripheral Vascular Diseases in the MeSH hierarchy.
- Blue Toe Syndrome
- Erythromelalgia
3 drugs (1 approved, 2 experimental)
- Livedo Reticularis
- May-Thurner Syndrome
4 drugs (3 approved, 1 experimental)
- Peripheral Arterial Disease
191 drugs (105 approved, 86 experimental)
- Phlebitis
8 drugs (5 approved, 3 experimental)
- Raynaud Disease
43 drugs (22 approved, 21 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (14)
Phase 3 trials (25)
- montelukast
- human fibrin
- beetroot juice
- carbon dioxide
- edifoligide
- gadofosveset trisodium
- warfarin
- ioversol
- gadopenteate dimeglumine
- niacin
- telcagepant
- acetaminophen
- propionyl l-carnitine
- allogeneic hematopoietic stem cells
- rifalazil
- bupivacaine
- treprostinil
- vancomycin
- alprostadil
- allogeneic adipose derived mesenchymal stem cell
- nl003
- riferminogene pecaplasmid
- gentamicin
- lovastatin
- gadobenate
Phase 2 trials (19)
- alfimeprase
- daprodustat
- paclitaxel
- hemoglobin glutamer 250
- bone marrow derived mesenchymal stem cells
- Parogrelil
- peripheral blood lymphocytes
- pf-00489791
- vepoloxamer
- ad2/hif-1alpha/vp16
- endometrial regenerative cells
- autologous cd34+ cells
- endothelial progenitor cells
- hgf plasmid
- multigeneangio
- vlts-589
- yinhsing
- hydroxyethyl starch
- fisetin
Phase 1 trials (10)
Organizations
Organization Involved with Phase 4 Indications (61)
- Bristol-Myers Squibb
- Amgen
- Merck
- Guerbet
- Pfizer
- Sanofi
- Mercator MedSystems, Inc.
- Otsuka
- Aultman Health Foundation
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Roma La Sapienza
- Arteriogenesis Competence Network
- Barnsley Hospital
- Baylor University
- Cathay General Hospital
- Changhua Christian Hospital
- Chung Shan Medical University
- Chimei Medical Center
- Hospital Universitario Getafe
- Kaohsiung Medical University
- Kuang Tien General Hospital
- Monash University
- National Cheng Kung University
- Northwestern University
- Seoul National University
- Shin Kong Wu Ho-Su Memorial Hospital
- University of Dundee
- University of Florence
- University of Florida
- University of Nebraska
- +31 more
Organization Involved with Phase 3 Indications (66)
- Takeda
- United Therapeutics
- Forest Laboratories
- Roche
- Novo Nordisk
- Bracco
- Anesiva, Inc.
- Bayer
- Beijing Northland Biotech. Co., Ltd.
- Kos Pharmaceuticals
- Leadiant Biosciences, Inc.
- Ixaka
- Omrix Biopharmaceuticals, Inc.
- Alvogen
- Dexa Medica Group
- Ethicon
- ZonMw: The Netherlands Organisation for Health Research and Development
- Anand, Sonia, M.D.
- University of Manitoba
- University of Pittsburgh
- Brown University
- Case Western Reserve University
- Harvard University
- Dartmouth University
- Hospital do Coracao
- Human Stem Cell Institute, Russia
- McMaster University
- Nanjing Medical University
- Ochsner Health System
- Rhode Island Hospital
- +36 more
Organization Involved with Phase 2 Indications (56)
- Biomarin
- Daiichi Sankyo
- Medistem
- Celgene
- Genzyme
- Arca Biopharma, Inc.
- Angiogenix
- Baxalta
- BioGenCell Ltd.
- Biopure Corporation
- Endovasc
- GlaxoSmithKline
- Juventas Therapeutics, Inc.
- Kobe University
- MultiGene Vascular Systems Ltd.
- Nissan Chemical Industries
- Reven Pharmaceuticals, Inc.
- Polysan, Ltd.
- TheraVasc Inc.
- Valentis
- Vericel Corporation
- TCA Cellular Therapy
- National Institutes of Health (NIH)
- National Center for Complementary and Integrative Health (NCCIH)
- Al-Ahliyya Amman University
- American Heart Association
- Cairo University
- Duke University
- Emory University
- Florida State University
- +26 more
Organization Involved with Phase 1 Indications (17)
- Venturis Therapeutics
- Pluristem Ltd.
- ev3
- Boehringer Ingelheim
- ReNeuron Limited
- Huazhong University of Science and Technology
- Mt. Sinai Medical Center, Miami
- South China Research Center for Stem Cell and Regenerative Medicine
- University of Naples Frederico II
- Icahn School of Medicine at Mount Sinai
- Affiliated Hospital of Military Medical Sciences
- Southern Medical University
- Humboldt University
- Washington University in St. Louis
- Foxhollow Technologies
- People's Liberation Army of China
- Deborah Heart and Lung Center
Organization Involved with Other Experimental Indications (23)
- Midwest Cardiovascular Research Foundation
- National Institute on Aging (NIA)
- United States Army
- University of Pennsylvania
- Maastricht University
- Boston University
- Chang Gung University
- Gottfried Wilhelm Leibniz Universität Hannover
- Sanford Health
- St. John's Research Institute
- University of Limerick
- University of Oklahoma
- University of Rome Tor Vergata
- University of Toronto
- Mayo Clinic
- University of Cambridge
- University of Angers
- University of Brescia
- National Health and Medical Research Council, Australia
- Clinical Trial Center Maastricht
- Spectranetics Corporation
- Cambridge Theranostics Ltd
- Reliant Pharmaceuticals